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BDNF contributes to both rapid and homeostatic alterations in 
AMPA receptor surface expression in nucleus accumbens 
medium spiny neurons
Jeremy M. Reimers1,†, Jessica A. Loweth1,†, and Marina E. Wolf1,*
1Department of Neuroscience, Rosalind Franklin University of Medicine and Science, 3333 Green 
Bay Road, North Chicago, IL 60064-3095
Abstract
Brain-derived neurotrophic factor (BDNF) plays a critical role in plasticity at glutamate synapses 
and the effects of repeated cocaine exposure. We recently showed that intracranial injection of 
BDNF into the rat nucleus accumbens (NAc), a key region for cocaine addiction, rapidly increases 
AMPA receptor (AMPAR) surface expression. To further characterize BDNF’s role in both rapid 
AMPAR trafficking and slower, homeostatic changes in AMPAR surface expression, we 
investigated the effects of acute (30 min) and long-term (24 h) treatment with BDNF on AMPAR 
distribution in NAc medium spiny neurons from postnatal rats co-cultured with mouse prefrontal 
cortex (PFC) neurons to restore excitatory inputs. Immunocytochemical studies showed that acute 
BDNF treatment increased cell surface GluA1 and GluA2 levels, as well as their co-localization, 
on NAc neurons. This effect of BDNF, confirmed using a protein crosslinking assay, was 
dependent on ERK but not AKT signaling. In contrast, long-term BDNF treatment decreased 
AMPAR surface expression on NAc neurons. Based on this latter result, we tested the hypothesis 
that BDNF plays a role in AMPAR “scaling down” in response to a prolonged increase in 
neuronal activity produced by bicuculline (24 h). Supporting this hypothesis, decreasing BDNF 
signaling with the extracellular BDNF scavenger TrkB-Fc prevented the scaling down of GluA1 
and GluA2 surface levels in NAc neurons normally produced by bicuculline. In conclusion, BDNF 
exerts bidirectional effects on NAc AMPAR surface expression, depending on duration of 
exposure. Furthermore, BDNF’s involvement in synaptic scaling in the NAc differs from its 
previously described role in the visual cortex.
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Brain-derived neurotrophic factor (BDNF) belongs to the family of neurotrophins that 
includes neurotrophin-3, neurotrophin-4/5, and nerve growth factor. Neurotrophins promote 
development, modulate synaptic function, and play a vital role in synaptic plasticity 
(Vicario-Abejón et al., 2002; Carvalho et al., 2008). BDNF is the most abundant 
neurotrophin expressed in the brain (Thoenen, 1995). Synthesized as a pro-peptide, the 
mature form of BDNF binds to tropomyosin receptor kinase B (TrkB), which is coupled to 
intracellular signaling cascades such as the Ras/extracellular signal-regulated protein kinase 
(ERK), phosphotidylinositol-3-kinase (PI3 kinase)/Akt, and phospholipase C γ (PLCγ) 
pathways (Kaplan & Miller, 2000). When released in response to glutamatergic activity (Lu, 
2003), BDNF activates these pathways and thereby contributes to multiple aspects of 
activity-dependent plasticity, including stimulation of local protein synthesis and dendritic 
spine formation, as well as facilitation of the induction and maintenance of long-term 
potentiation (LTP) (Bramham & Messaoudi, 2005; Waterhouse & Xu, 2009).
Not surprisingly, BDNF has also been implicated in behavioral and cellular plasticity 
produced by drugs of abuse, including cocaine (Russo et al., 2009; McGinty et al., 2010; 
Pickens et al., 2011). Like other forms of plasticity (Shepherd & Huganir, 2007), cocaine-
induced plasticity can involve the trafficking of α-amino-3-hyroxy-5-methyl-4-isoxazole-
propionic acid receptors (AMPARs) (Wolf, 2010; Pierce & Wolf, 2013). The nucleus 
accumbens (NAc) is a critical brain region for motivated behavior and addiction (Sesack & 
Grace, 2010). Studies of animal models of cocaine craving and relapse indicate that these 
behaviors are associated with altered BDNF levels in the NAc, as well as alterations in 
AMPAR surface and synaptic expression in the NAc (see Discussion). We wondered if 
BDNF might play a role in cocaine-induced AMPAR plasticity, based on in vitro studies 
showing increased cell surface and synaptic levels of AMPAR subunits following BDNF 
exposure (Narisawa-Saito et al., 2002; Caldeira et al., 2007; Li & Keifer, 2008; 2009) and 
our recent demonstration that intracranial injection of BDNF increases GluA1 surface 
expression in the NAc of adult drug-naïve rats (Li & Wolf, 2011).
The goal of the present study was to further characterize the interaction between BDNF and 
NAc AMPARs using a primary culture system amenable to direct measurements of AMPAR 
trafficking. In this system, characterized previously, medium spiny neurons (MSN) from 
postnatal rat NAc are co-cultured with prefrontal cortex (PFC) neurons from mice 
expressing enhanced cyan fluorescent protein (ECFP); the PFC neurons restore excitatory 
input onto the MSN, but can be distinguished from MSN based on fluorescence (Sun et al., 
2008; Sun & Wolf, 2009). We found that acute BDNF treatment (30 min) increases 
AMPAR surface expression in an ERK-dependent manner, while long-term BDNF 
treatment (24 h) decreases AMPAR surface expression. Furthermore, BDNF is required for 
homeostatic reductions in AMPAR surface expression (synaptic scaling) in response to a 
prolonged increase in excitatory transmission. The latter finding may be relevant to BDNF’s 
role in addiction, as the relatively slow time-scale of synaptic scaling, at least compared to 
Hebbian plasticity, makes it an interesting candidate for mediating slow behavioral changes 
occurring during drug exposure and withdrawal.
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As described previously (Sun et al., 2008, Sun & Wolf, 2009), postnatal day 1 (P1) rats from 
pregnant Sprague-Dawley rats (Harlan, Indianapolis, IN, USA) were decapitated and used to 
obtain NAc neurons, while PFC cells were obtained from P1 offspring of transgenic mice 
expressing enhanced cyan fluorescent protein (ECFP) [strain B6.129(ICR)-Tg(ACTB-
ECFP)1Nagy/J; The Jackson Laboratory, Bar Harbor, ME, USA]. The ECFP transgenic 
mouse line was maintained by mating homozygous ECFP male and female mice in house. 
All offspring express ECFP. All animal procedures were in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved 
by the Institutional Animal Care and Use Committee of Rosalind Franklin University of 
Medicine and Science.
Primary neuronal cultures
NAc/PFC co-cultures were prepared as previously described (Sun et al., 2008; Sun & Wolf, 
2009). Briefly, the PFC of P1 ECFP-expressing mice was dissociated with papain at 37°C 
and plated at a density of 30,000 cells/well onto coverslips coated with poly-D-lysine (100 
μg/mL; Sigma Aldrich, St. Louis, MO, USA) in 24-well plates. Two to three days later, the 
NAc from P1 rats was dissociated with papain and plated at a density of 30,000 cells/well 
with the PFC cells. The NAc/PFC co-cultures were grown in Neurobasal medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 2mM GlutaMAX, 0.5% Gentamicin 
and 2% B27 (Invitrogen). Half of the medium was replaced every 4 days. Cultures were 
used for immunocytochemical experiments between weeks 2 and 3 after plating the NAc 
neurons. For experiments involving Western blotting, the NAc from P1 rats was dissected 
and plated at a higher density (200,000 cells/well). The cultures were grown as described 
above. Cultures were used between 2 and 3 weeks after plating.
Drug treatments
NAc/PFC co-cultures and NAc cultures were either kept in control medium or incubated 
with BDNF (25 ng/mL; Sigma Aldrich), the MAPK/ERK kinase (MEK1/2) inhibitor U0126 
(10 μM; Cell Signaling Technology, Danvers, MA, USA), the PI3 kinase inhibitor 
LY294002 (25 μM; Cell Signaling Technology) or BDNF + either inhibitor for 30 min or 24 
h, as indicated, in Neurobasal media. In the synaptic scaling experiments, NAc/PFC co-
cultures were kept in control medium or incubated with bicuculline (20 µM; Tocris 
Bioscience, Ellisville, MD, USA), TrkB-Fc (0.5 µg/mL; Sigma), or TrkB-Fc + bicuculline 
for 24 h.
Immunocytochemistry
For cell surface GluA1 and GluA2 double immunostaining, live neurons were incubated 
with polyclonal antibody to the extracellular N-terminal domain of GluA1 (1:15, PC246, aa 
253–267; Calbiochem, La Jolla, CA, USA;) and monoclonal antibody to the extracellular N-
terminal domain of GluA2 (1:20; MAB397, aa 175–430; Millipore, Billerica, MA, USA) in 
NeuroBasal media (15 min, 37°C). Cells were then fixed with 4% paraformaldehyde, 
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blocked with 5% donkey serum in phosphate-buffered saline for 1 h and incubated for 1 h 
with Cy3 conjugated donkey anti-rabbit 2° antibody (1:500; Jackson ImmunoResearch, 
West Grove, PA, USA) and Alexa 488 conjugated donkey anti-mouse 2° antibody (1:1000; 
Invitrogen) without permeabilization. Incubations were performed at room temperature (RT; 
~21°C).
Image analysis
Images were analyzed as described previously (Sun et al., 2005; 2008). NAc and PFC 
neurons were distinguished by fluorescence and morphology (Sun et al., 2008). Images of 
NAc MSN adjacent to PFC pyramidal neurons, selected under phase contrast imaging to 
avoid experimenter bias based on the intensity of fluorescence staining, were acquired with 
a Nikon inverted microscope using a 40 × oil objective, an ORCA-ER digital camera and 
MetaMorph software (Universal Imaging, Downington, PA, USA). All experimental groups 
compared were from the same culture preparation and were processed simultaneously. 
Approximately 4–6 cells from at least 5 different wells for each group were analyzed. For 
each image, total AMPAR surface area in a fixed length (15 µm) of process, located at least 
one soma diameter away from the soma, was measured using a threshold set at least 2× 
higher than average background fluorescence in unstained areas. We used AMPAR area 
rather than intensity as a measure of AMPAR density, as in our prior studies (Sun et al., 
2005; Sun et al., 2008; Sun and Wolf, 2009), because we have found area to be a more 
sensitive measure.
Surface receptor crosslinking
After the appropriate BDNF stimulation time (30 min or 24 h), cultures were washed two 
times with HBSS (Invitrogen) and then incubated for 10 min with 2mM 
bis(sulfosuccinimidyl)suberate (BS3; Pierce, Rockford, IL, USA) in HBSS at 37°C as 
described previously (Gao & Wolf, 2008; Sun et al., 2008) to selectively crosslink surface-
expressed receptors. This increases their apparent molecular weight, enabling them to be 
distinguished from unmodified intracellular AMPAR subunits by SDS-PAGE and Western 
blotting. Crosslinking was terminated by quenching the reaction with 100mM glycine for 10 
min at 4°C.
Western blotting
Cultures were scraped into ice-cold lysis buffer containing phosphatase and protease 
inhibitors [25 mM HEPES, pH7.4, 500 mM NaCl, 2 mM EDTA, 1 mM DTT, 1 mM 
phenylmethyl sulfonyl fluoride, 20 mM NaF, 1 mM sodium orthovanidate, 10 mM sodium 
pyrophosphate, 1 μM microcystin-LF, 1 μM okadaic acid, 1X protease inhibitor cocktail set 
I (Calbiochem), and 0.1% Nonidet P-40 (v/v)]. Homogenates were made by sonicating lysed 
cells 3 times for 5 s on ice and centrifuging at 12,000 × g for 2 min. The supernatant was 
aliquotted and stored at −80°C. Protein concentration for each sample was determined using 
the Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). Samples (20 μg total protein per 
lane) were run on 4–15% gradient Tris-HCl gels (BioRad). For immunoblotting, proteins 
were transferred to PVDF membranes. Membranes were washed in dH2O and blocked with 
1% goat serum with 5% non-fat dry milk in 0.05% Tween-20 in TBS, pH 7.4 for 1 hr at RT. 
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Membranes were then incubated with one of the following primary antibodies overnight at 
4°C: GluA1 (1:1000; PA137776, Pierce), GluA2 (1:1000; AB1768, Millipore), AKT 
(1:1000; 9272, Cell Signaling Technology), phosphorylated AKT (P-AKT; Ser473) (1:1000; 
4058, Cell Signaling Technology), P-AKT (Thr308) (1:1000; 4056, Cell Signaling 
Technology), p-44/42 MAPK (ERK1/2) (1:1000; 9101, Cell Signaling Technology), 
phosphorylated p-44/42 MAPK (P-ERK1/2) (1:1000; 4377, Cell Signaling Technology), 
eEF2 (1:1000; 2332, Cell Signaling Technology), phosphorylated eEF2 (P-eEF2) (1:1000; 
2331, Cell Signaling Technology), mTOR (1:1000; 2972, Cell Signaling Technology), or 
phosphorylated mTOR (P-mTOR) (1:1000; 2971, Cell Signaling Technology). Membranes 
were washed with TBS-Tween solution, incubated for 60 min with HRP-conjugated anti-
rabbit IgG or anti-mouse IgG (1:10,000; Millipore), and washed again with TBS-Tween 
followed by TBS. Membranes were rinsed with dH2O, immersed in chemiluminescence 
(ECL) detecting substrate (GE Healthcare, Little Chalfont, UK) for 1 min and visualized 
using HyperFilm ECL. Phospho-antibodies were stripped from the membrane by incubating 
in 62.5 mM Tris, pH 6.8, 2% SDS, and 100 mM 2-mercaptoethanol for 60 min. Blots were 
then probed with the corresponding phosphorylation-independent antibody. Bands of 
interest were quantified using TotalLab (Nonlinear Dynamics Ltd., Newcastle, UK) and data 
were normalized to total protein in the lane determined with Ponceau S staining.
Statistical Analysis
For immunocytochemistry experiments (Figs. 1, 4 and 5), data were analyzed with a 
Kruskal-Wallis one-way ANOVA on ranks. When a significant group effect was found, post 
hoc comparisons were performed using a Dunn’s test, unless otherwise noted. For 
immunoblotting experiments (Figs. 2 and 3), data were analyzed with a one-way ANOVA to 
compare multiple groups. When a significant group effect was found, post hoc comparisons 
were performed using a Dunnett’s test. The criterion for significance was set at P < 0.05 (n, 
number of cells or lanes analyzed). All data were analyzed and all graphs were generated 
using SigmaStat and SigmaPlot software, respectively (Systat Software Inc., San Jose, CA, 
USA).
Results
Acute BDNF treatment increases while long-term BDNF treatment decreases AMPAR 
surface expression in NAc MSN
As in other regions (Wenthold et al., 1996; Lu et al., 2009; Reimers et al., 2011), the 
majority of AMPAR in the NAc are GluA1A2 receptors, along with GluA2A3 and a 
minority population (~10%) of GluA2-lacking receptors (Boudreau et al., 2007; Conrad et 
al., 2008; Reimers et al., 2011). Our prior studies of NAc MSN co-cultured with PFC 
neurons have implicated GluA1A2 receptors in homeostatic synaptic scaling, although these 
MSN also express a substantial population of homomeric GluA1 receptors on their cell 
surface (Sun et al., 2008; Sun & Wolf, 2009). Therefore, we focused on GluA1 and GluA2 
in the present study.
To directly assess the effect of BDNF stimulation on AMPAR trafficking in NAc neurons, 
NAc/PFC co-cultures were stimulated for 30 min or 24 h with BDNF (25ng/mL; 
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concentration based on Rutherford et al., 1998) followed by live-cell labeling with 
antibodies directed against the extracellular N-terminal regions of GluA1 and GluA2. The 
30 min time was selected to study acute effects of BDNF, while the 24 h time was selected 
because elevating or blocking activity for 24 h is sufficient to elicit synaptic scaling in 
NAc/PFC co-cultures (Sun & Wolf, 2009). Our analysis was restricted to MSN of the NAc, 
which were identified based on morphology and absence of the cyan fluorescence that 
serves as a marker for PFC neurons in the co-cultures (see Methods). Interestingly, 
incubation of the co-cultures with BDNF for 30 min significantly increased surface AMPAR 
surface expression while incubation with BDNF for 24 h significantly decreased AMPAR 
surface expression (Fig. 1). Analysis by Kruskal-Wallis one-way ANOVA on ranks revealed 
a significant difference between the three treatment groups (control, 30 min BDNF, 24 h 
BDNF) in levels of cell surface GluA1 (H=26.78, P<0.001), GluA2 (H=41.46, P<0.001) and 
GluA1/A2 co-localization (H=39.12, P<0.001). Dunn’s test post-hoc comparisons revealed 
that, compared to the control group, incubation with BDNF for 30 min produced a 
significant increase in surface expression of GluA1 (Q=2.70, P<0.05), GluA2 (Q=2.46, 
P<0.05) and GluA1/A2 co-localization (Q=3.08, P<0.05) (Fig. 1B–D). In contrast, Dunn’s 
test post-hoc comparisons revealed that, compared to the control group, incubation with 
BDNF for 24 h produced a significant decrease in cell surface GluA2 (Q=3.35, P<0.05) and 
GluA1/A2 co-localization (Q=2.57, P<0.05) (Fig. 1C,D). Although not significant (Q=1.96, 
P>0.05), a trend was observed towards decreased surface expression of GluA1 after 24 h of 
BDNF treatment (59% of control, Fig. 1B), which reached statistical significance when 
directly compared to the control group using a Mann-Whitney U test (U=138, P=0.023).
To confirm the results using another approach, we stimulated high-density NAc cultures 
with BDNF (25ng/mL) for 30 min or 24 h. Following BDNF incubation, cell surface 
proteins were crosslinked using the membrane impermeable, bi-functional crosslinking 
reagent BS3 (Boudreau & Wolf, 2005; Boudreau et al., 2012). SDS-PAGE followed by 
immunoblotting was used to separate the crosslinked surface proteins from the non-
crosslinked intracellular proteins (Fig. 2A, B). We used “pure” NAc cultures for this 
experiment because PFC neurons in the co-cultures would have contributed to our protein 
measurements and higher density cultures in order to provide a stronger signal.
After incubation with BDNF for 30 min, the crosslinking experiments in high-density NAc 
cultures revealed a significant increase in GluA2 surface expression (Fig. 2D; one-way 
ANOVA: F(2,9) = 21.73, P = 0.006; 30 min BDNF vs. control, P < 0.05, Dunnett’s test) and 
a trend for GluA1 (Fig. 2C; one-way ANOVA: F(2,9) = 2.39, P = 0.14; surface GluA1 was 
140% of control). These results are generally consistent with those obtained using 
immunocytochemistry (Fig. 1). BDNF did not significantly alter intracellular levels of 
GluA1 or GluA2 measured with the crosslinking assay (Fig. 2E,F; GluA1, one-way 
ANOVA: F(2,9) = 0.16, P = 0.86; GluA2, one-way ANOVA: F(2,9) = 1.72, P = 0.23). This 
could indicate that the BDNF-induced increase in AMPAR surface levels is due to synthesis 
of new AMPAR subunits that are targeted to the cell surface, although we cannot rule out 
the possible contribution of AMPAR redistribution from intracellular to surface pools. 
Incubation with BDNF (25ng/mL) for 24 h produced trends in the opposite direction for 
surface GluA1 and GluA2 (72% and 64% of control, respectively; P > 0.05 vs. control, 
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Dunnett’s test) (Fig. 2C,D). The presence of excitatory synaptic inputs to MSN in the 
NAc/PFC co-cultures but not the high-density NAc cultures could explain why 24 h of 
BDNF incubation produced statistically significant decreases in AMPAR surface expression 
in the former (Fig. 1) but only trends in the latter. Taken together, immunocytochemical and 
protein crosslinking experiments indicate that acute BDNF incubation (30 min) increases 
AMPAR surface expression on MSNs of the NAc, while long-term BDNF incubation (24 h) 
has the opposite effect.
ERK and AKT are activated in the NAc by incubation with BDNF
In order to identify signaling pathways in NAc MSN that mediate the BDNF-induced 
changes in AMPAR surface expression, high-density NAc cultures were incubated with 
BDNF (25ng/mL) for 30 min or 24 h and then harvested in buffer containing protease and 
phosphatase inhibitors. Immunoblotting was used to assess phosphorylation of ERK1/2 (P-
ERK1/total ERK1 and P-ERK2/total ERK2), AKT [P-AKT (Ser473)/total AKT and P-AKT 
(Thr308)/total AKT], mTOR (P-mTOR/total mTOR), and eEF2 (P-eEF2/total eEF2). These 
pathways were selected because they are downstream of the TrkB receptor (see 
Introduction). High-density NAc cultures are ideal for screening multiple pathways because 
they provide more protein for immunoblotting than the NAc/PFC co-cultures, and do not 
contain PFC proteins which would contribute to immunoblotting results and thus obscure 
selective analysis of NAc signaling pathways. Acute incubation with BDNF (30 min) 
significantly increased phosphorylation of ERK1, ERK2, and AKT (at both Ser473 and 
Thr308) (Fig. 3A–D; ERK1, one-way ANOVA: F(2,9) = 18.19, P < 0.05; ERK2, one-way 
ANOVA: F(2,9) = 34.93, P < 0.05; AKT Ser473, F(2,9) = 5.32, P < 0.05; AKT Thr308, one-
way ANOVA: F(2,9) = 12.41, P < 0.05; Dunnett’s tests, all P < 0.05 for 30 min BDNF vs. 
control), while only ERK1 and ERK2 phosphorylation remained significantly elevated after 
long-term BDNF incubation (24 h) (Fig. 3A and B, respectively; Dunnett’s test, both P < 
0.05 for 24 h BDNF vs. control). Phosphorylation of mTOR and eEF2 were not significantly 
altered by BDNF incubation at either time-point (Fig. 3E,F; mTOR, one-way ANOVA: 
F(2,9) = 0.14, P = 0.87; eEF2, one-way ANOVA: F(2,9) = 1.10, P = 0.38).
BDNF requires ERK1/2 activation to increase AMPAR surface expression in the NAc
Given that ERK1/2 phosphorylation is significantly increased by BDNF after both 30 min 
and 24 h of BDNF incubation and that AKT phosphorylation is significantly increased after 
30 min of BDNF incubation, we wanted to determine whether either of these pathways is 
required for BDNF-induced changes in AMPAR surface expression. To accomplish this, 
NAc/PFC co-cultures were treated with the MAPK/ERK kinase (MEK1/2) inhibitor, U0126 
(10μM), or the PI3 kinase inhibitor, LY294002 (25μM), alone or in combination with 
BDNF, for 30 min or 24 h. The inhibitors were added 20 min prior to BDNF. At the 30 min 
time-point, U0126 abolished the BDNF-induced increase in surface GluA1 and GluA2 
expression as well as the increase in surface GluA1/A2 co-localized area (Fig. 4A–C). 
Analysis by Kruskal-Wallis one-way ANOVA on ranks revealed significant differences 
among the 6 treatment groups in cell surface levels of GluA1 (H = 61.16, P < 0.001), GluA2 
(H = 44.45, P < 0.001) and GluA1/A2 co-localization (H = 59.84, P<0.001). Dunn’s test 
post-hoc comparisons showed that, in the BDNF + U0126 group, surface levels of GluA1 
(Q=1.16), GluA2 (Q=0.23) and GluA1/A2 co-localization (Q=0.56) did not differ from the 
Reimers et al. Page 7













control group (P > 0.05). However, the PI3 kinase inhibitor, LY294002, was unable to block 
the BDNF-induced increases in surface GluA1, GluA2, or GluA1/A2 co-localization (Fig. 
4A–C; Dunn’s tests, Q = 5.47, 4.75 and 5.49, respectively; P < 0.05 vs. control for all 
measures). Acute incubation with each inhibitor alone had no effect on surface levels of 
GluA1, GluA2, or GluA1/A2 co-localization (Fig. 4A–C; P>0.05 vs. control). Next, we 
examined the effects of long-term (24 h) incubation with U0126 (10μM) or LY294002 
(25μM), alone or in combination with BDNF (25ng/mL), on AMPAR surface expression. 
Consistent with the results shown in Fig. 1, long-term BDNF treatment significantly 
decreased surface levels of GluA1, GluA2 and the area of GluA1/A2 co-localization. 
However, neither inhibitor affected either the magnitude of the BDNF-induced decrease in 
AMPAR surface expression or basal AMPAR surface expression in the absence of BDNF 
treatment (Fig. 4D–F). Thus, analysis by Kruskal-Wallis one-way ANOVA on ranks 
revealed no difference in AMPAR surface expression between all BDNF-exposed groups 
(BDNF, U0126+BDNF, LY294002 + BDNF) nor between the three groups that were not 
exposed to BDNF (Control, U0126, LY294002; P > 0.05). Subsequent ANOVAs revealed a 
significant decrease in all 24 h BDNF groups compared to all non-BDNF exposed groups 
for surface GluA1 (H = 14.92, P < 0.001), GluA2 (H = 22.06, P<0.001) and GluA1/A2 co-
localization (H = 9.63, P = 0.002). Taken together, these results suggest that activation of 
ERK1/2 is necessary for acute BDNF incubation (30 min) to increase surface AMPAR 
expression, whereas this is not the case for the decrease in AMPAR surface expression 
produced by long-term BDNF exposure (24 h).
BDNF signaling is required for “scaling down” of AMPAR surface expression in NAc MSN 
in response to a prolonged increase in neuronal activity
To determine if the decrease in AMPAR surface expression observed following long-term 
BDNF exposure was related to synaptic scaling, we assessed whether interfering with BDNF 
activity would prevent the decrease in GluA1 and GluA2 surface expression (“scaling 
down”) normally observed in NAc neurons following a prolonged increase in excitatory 
transmission (Sun & Wolf, 2009). NAc/PFC co-cultures were treated for 24 h with the 
GABAA receptor antagonist bicuculline (20 µM) alone or in the presence of a membrane-
impermeable scavenger of extracellular BDNF, TrkB-Fc (0.5 µg/mL; concentration based on 
Jourdi et al., 2009). A separate group was treated for 24 h with TrkB-Fc alone (0.5 µg/mL). 
As reported previously (Sun & Wolf, 2009), enhancing excitatory synaptic activity by 
blocking GABAA receptor transmission with bicuculline produced a significant decrease in 
AMPAR surface expression (Fig. 5A–C). Analysis by Kruskal-Wallis one-way ANOVA on 
ranks revealed a significant difference between the four treatment groups (control, 
bicuculline, bicuculline +TrkB-Fc, TrkB-Fc) in surface levels of GluA1 (H = 17.25, 
P<0.001), GluA2 (H = 15.81, P = 0.001) and GluA1/A2 co-localization (H = 17.73, P < 
0.001). Dunn’s test post-hoc comparisons revealed a significant decrease in surface GluA1, 
GluA2 and GluA1/A2 co-localization in the bicuculline-treated group compared to the 
control group (Q = 3.39, 2.77 and 2.89, respectively, P < 0.05). Interestingly, decreasing 
BDNF signaling in the presence of bicuculline prevented the bicuculline-induced decrease in 
surface GluA1, GluA2 and GluA1/A2 co-localization (Q = 2.68, 2.99 and 2.92, respectively; 
P < 0.05, bicuculline vs. bicuculline + TrkB-Fc). Incubation for 24 h with TrkB-Fc alone did 
not significantly alter AMPAR surface expression (Fig. 5A–C; P > 0.05 TrkB-Fc compared 
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to control), which could simply be due to low endogenous BDNF levels under basal 
conditions since TrkB-Fc competes with native TrkB receptors for BDNF (Binder et al., 
1999). However, incubation with TrkB-Fc alone produced trends for AMPAR surface 
expression (GluA1, 128% of control; GluA2, 136% of control; GluA1A2 co-localization, 
179% of control; Fig 5A–C), potentially suggesting that low levels of endogenous BDNF 
may be exerting small effects that are opposed by TrkB-Fc. Together, these results indicate 
that BDNF release mediates the “scaling down” of AMPAR surface expression in NAc 
MSN produced by a long-term enhancement in synaptic activity.
Discussion
MSN, which comprise approximately 90% of neurons in the NAc, are GABAergic 
projection neurons that play a critical role in motivated behaviors including addiction 
(Meredith et al., 2008). We have previously developed and characterized a NAc/PFC co-
culture system in which PFC pyramidal neurons make excitatory synapses onto the MSN; 
AMPAR trafficking at these synapses can be studied using immunocytochemical methods 
(Sun et al., 2008; Sun & Wolf, 2009). Our present results show that acute BDNF treatment 
(30 min) increases AMPAR surface expression in MSN in NAc/PFC co-cultures, whereas 
long-term BDNF (24 h) decreases AMPAR surface expression. Furthermore, BDNF appears 
to mediate the decrease in AMPAR surface expression associated with synaptic scaling 
elicited by chronic elevation of neuronal activity with bicuculline (24 h). Although there are 
caveats associated with extrapolating from in vitro to in vivo systems (see below), these 
results help define basic synaptic mechanisms operating in MSN of the NAc, which 
facilitates the development of hypotheses to account for in vivo findings on cocaine-induced 
changes in BDNF and AMPAR levels in this brain region.
Acute BDNF treatment produces a rapid increase in AMPAR surface expression
In order to determine the effects of BDNF treatment on AMPAR surface expression and the 
signaling pathways involved, we used two separate in vitro approaches, 
immunocytochemical analysis of NAc/PFC co-cultures and surface receptor crosslinking in 
high-density “pure” NAc cultures. The former is preferable for localizing receptors, whereas 
the latter offers advantages for screening signaling pathways via immunoblotting since more 
protein is available and immunoblotting results are not “contaminated” by the presence of 
PFC proteins. We found that acute (30 min) treatment of cultures with BDNF (25ng/mL) 
increases surface expression of the AMPAR subunits GluA1 and GluA2, along with their 
co-localization. Our results are in general agreement with results from other in vitro systems. 
Caldeira et al. (2007) showed that treatment of hippocampal cultures with BDNF for 30 min 
increases levels of surface GluA1, an effect that is dependent on translation. Furthermore, in 
an organotypic slice preparation, they showed that when GluA1 is over-expressed, leading 
to formation of homomeric GluA1 receptors, BDNF can induce synaptic insertion of these 
receptors (Caldeira et al., 2007). Narisawa-Saito et al. (2002), using cultured cortical 
neurons, showed that BDNF induced a translocation of GluA2-containing AMPARs to the 
surface that is evident within 30 min. Nakata & Nakamura (2007) showed that BDNF 
rapidly increases AMPAR trafficking to the postsynaptic density in cultured cortical 
neurons. Finally, BDNF treatment of turtle brain stem preparations enhances synaptic 
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delivery of GluA1- and GluA4-containing AMPARs (Li & Keifer, 2008; 2009; Keifer & 
Zheng, 2010). In two of the studies mentioned above, the rapid BDNF-induced increase in 
AMPAR surface expression was followed by a slower increase in total protein levels of 
AMPAR subunits (Caldeira et al., 2007; Narisawa-Saito et al., 2002; see also Narisawa-
Saito et al., 1999a,b) which was paralleled by an increase in AMPAR-interacting proteins 
(Jourdi et al., 2003). Our immunocytochemical studies, which analyzed AMPAR levels on 
the surface of neuronal processes, do not provide information about total cellular AMPAR 
protein levels, whereas our protein crosslinking results may suggest an increase in total 
GluA1 and GluA2 protein levels after 30 min of BDNF incubation.
An interesting aspect of BDNF’s effects on AMPAR trafficking in different in vitro 
preparations (summarized above) is that they indicate the potential for BDNF to regulate 
both GluA2-containing AMPARs and GluA2-lacking Ca2+-permeable AMPARs (CP-
AMPARs). Whether the type of AMPAR regulated reflects differences in cell types, brain 
regions, or experimental conditions is unclear. Our present results indicate that BDNF 
regulates GluA2-containing AMPARs (GluA1A2) in MSN in NAc/PFC co-cultures. This is 
consistent with our prior work in the same culture system demonstrating that synaptic 
scaling in MSN involves GluA1A2 receptors, despite the existence of a substantial 
population of homomeric GluA1 receptors in these cultured MSN (Sun & Wolf, 2009). 
However, we cannot rule out a role for homomeric GluA1 receptors in rapid AMPAR 
trafficking between intracellular, extrasynaptic and synaptic pools elicited by D1 dopamine 
receptor stimulation or glycine-induced synaptic activation of MSN, as only GluA1 was 
measured in these studies (Sun et al., 2008). Returning to BDNF, while our current in vitro 
results indicate a selective effect on GluA1A2 receptors, we obtained a different result when 
we examined BDNF’s effect on AMPAR trafficking in the NAc of adult rats (Li & Wolf, 
2011). In this prior study, we observed that micro-injection of BDNF into the core subregion 
increased cell surface levels of GluA1 but not GluA2 or GluA3 30 min after BDNF 
injection, suggesting increased CP-AMPAR levels; this effect was transient, returning to 
baseline 3 h post-injection (Li & Wolf, 2011). Potential explanations for the different 
findings include the age of the neurons and the effects of many neurotransmitters and 
modulators in the intact NAc that are absent in cultures.
ERK activation is necessary for the acute BDNF-induced increase in surface AMPAR 
expression
We next wanted to determine which pathways downstream of BDNF signaling are activated 
by acute and long-term treatment of NAc MSNs with BDNF. We chose to investigate 
ERK1/2, AKT, mTOR, and eEF2. ERK is activated through the Ras-MAPK/ERK signaling 
cascade, downstream of BDNF binding to the TrkB receptor, via a series of phosphorylation 
events (Frank et al., 1996). ERK activation subsequently leads to activation of transcription 
factors such as cAMP-response element binding protein (CREB) (Fields et al., 1997) and 
thus influences transcriptional events (Whitmarsh, 2007), potentially including BDNF-
induced changes in the synthesis of new AMPAR subunits (Caldeira et al., 2007; Narisawa-
Saito et al., 2002; see also Narisawa-Saito et al., 1999a,b). However, ERK also has non-
transcriptional actions (Sweatt, 2004), including an important role in AMPAR trafficking 
(see below). AKT phosphorylation is indicative of activation of the PI3 kinase signaling 
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pathway, another downstream target of BDNF (Sarbassov et al., 2005). BDNF can trigger 
local protein synthesis through activation of mTOR (Takei et al., 2004) and recent evidence 
has shown that the activation of mTOR by BDNF increases GluA1 transcription (Slipczuk et 
al., 2009). The protein eEF2, which is required for the elongation step of translation 
(Ryazanov et al., 1988), is also involved in local protein synthesis stimulated by BDNF 
(Inamura et al., 2005).
We observed that acute (30 min) stimulation of NAc cultures with BDNF leads to the 
phosphorylation of ERK and AKT, but not mTOR or eEF2. This discovery led us to the next 
experiment in which we inhibited MEK1/2 (upstream from ERK1/2) with the inhibitor 
U0126 or PI3 kinase (upstream of AKT) with the inhibitor LY294002 to determine if 
activation of either pathway is required for BDNF-induced changes in AMPAR surface 
expression. We found that MEK1/2 inhibition and not PI3 kinase inhibition prevented the 
acute BDNF-induced increase in AMPAR surface expression. This is in agreement with 
work showing that ERK activation is necessary for BDNF-induced synaptic delivery of 
GluA1 and GluA4 in turtle brain stem (Li & Keifer, 2008; 2009). Similarly, work in other 
systems has demonstrated that ERK activation is part of the cascade leading to activity-
dependent increases in surface AMPAR expression (Zhu et al., 2002; Qin et al., 2005; 
Keifer et al., 2007). Our lab has also shown a positive relationship between ERK activation 
and AMPAR surface expression in the adult rat NAc during withdrawal from repeated 
cocaine injections (Boudreau et al., 2007, 2009). Of course, many additional signaling 
pathways also contribute to AMPAR synaptic insertion (Derkach et al., 2007; Shepherd & 
Huganir, 2007; Anggono & Huganir, 2012).
BDNF mediates “scaling down” of AMPAR surface expression in NAc neurons
Synaptic scaling is a form of homeostatic plasticity in which prolonged increases in neuronal 
activity lead to a compensatory decrease in excitatory transmission that is often mediated by 
a decrease in synaptic AMPAR levels (scaling down). Prolonged activity blockade produces 
the opposite effect, that is, an increase in excitatory transmission that is often mediated by 
increased synaptic AMPAR levels (scaling up) (Turrigiano, 2008). As BDNF is synthesized 
and released in an activity dependent manner (Lu, 2003), BDNF levels could serve as 
signals for changes in neuronal activity and thereby mediate synaptic scaling. Indeed, 
extensive studies in visual cortex have shown that decreasing neuronal activity (e.g., with 
TTX) leads to a decrease in endogenous BDNF release that is responsible for scaling up of 
mEPSC amplitude in pyramidal neurons. Thus, the increase in mEPSC amplitude produced 
by prolonged activity blockade with TTX was prevented by co-application of BDNF, 
whereas scavenging BDNF with a TrkB-IgG fusion protein reproduced the effect of activity 
blockade (Rutherford et al., 1998). On the other hand, 48 h incubation with BDNF alone did 
not decrease mEPSC amplitude (Rutherford et al., 1998), and scavenging BDNF did not 
affect scaling down produced by chronic depolarization with KCl (Leslie et al., 2001). Thus, 
BDNF is not a bidirectional mediator of synaptic scaling in pyramidal neurons of the visual 
cortex. While it mediates scaling up, other cellular messengers must be responsible for 
scaling down of synaptic strength in visual cortical pyramidal neurons in response to 
prolonged increases in activity (Rutherford et al., 1998; Turrigiano, 2008).
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These prior findings were important in motivating us to test the effects of longer-term (24 h) 
BDNF exposure on AMPAR trafficking in NAc neurons. Whereas acute (30 min) BDNF 
treatment markedly increased AMPAR surface expression, the longer incubation produced 
the opposite effect, namely a decrease in AMPAR surface expression. Although this is not 
what would have been predicted based on results in visual cortex (above), we proceeded to 
test the possibility that, in NAc neurons, BDNF plays a role in scaling down of AMPAR 
surface expression in response to prolonged increases in activity. As expected from our past 
results (Sun & Wolf, 2009), 24 h treatment with the GABAA receptor antagonist bicuculline 
decreased GluA1 and GluA2 surface expression, indicative of scaling down. This effect was 
blocked when we co-applied the neurotrophin scavenger TrkB-Fc and thereby decreased 
BDNF signaling. Thus, increasing exogenous BDNF levels decreased AMPAR surface 
expression and blocking endogenous BDNF transmission with TrkB-Fc prevented 
bicuculline-induced scaling down of AMPAR surface expression. Together, these results 
suggest that increasing neuronal activity with bicuculline leads to increased BDNF release, 
which in turn scales down AMPAR surface expression. Although we did not distinguish 
synaptic from extrasynaptic AMPAR pools in the present study, we showed previously, in 
an identical co-culture system, that both synaptic and extrasynaptic AMPARs “scale up” in 
response to bicuculline; furthermore, scaling of surface AMPARs in response to activity 
blockade or enhancement is accompanied by parallel changes in total AMPAR subunit 
levels measured in permeabilized neurons (Sun & Wolf, 2009).
It is surprising that BDNF mediates scaling down of AMPAR surface expression in cultured 
NAc MSN (present results), but scaling up in pyramidal neurons in visual cortical cultures 
(Rutherford et al., 1998). One potentially relevant difference is that principal neurons of the 
NAc (MSN) are inhibitory GABAergic neurons, while those of the visual cortex are 
excitatory pyramidal neurons. Interestingly, whereas addition of exogenous BDNF does not 
alter mEPSC amplitude in pyramidal neurons in visual cortical cultures, it increases mEPSC 
amplitude in GABAergic interneurons in the same cultures (Rutherford et al., 1998). This is 
intriguing, as it shows that the nature of BDNF’s effect can vary with cell phenotype. 
However, this effect in the cortical GABAergic interneurons is still opposite to what we 
observe in GABAergic MSN of the NAc, so variables other than GABAergic phenotype 
must be important. Further supporting this, whereas long-term activity blockade (TTX or 
AMPAR antagonists) produces scaling up of AMPARs in cultured NAc MSN (Sun & Wolf, 
2009), the same activity blockade fails to scale up mEPSC amplitude in GABAergic 
interneurons in visual cortical cultures (Turrigiano et al., 1998). Another consideration is 
that activity levels in NAc-PFC co-cultures are likely to be lower than in visual cortical 
cultures, due to a population of GABAergic principal neurons in the former but not the 
latter. Therefore, BDNF production in cortical cultures may be near-saturating under control 
conditions (see Rutherford et al., 1998 for discussion), whereas lower basal BDNF 
production in NAc-PFC co-cultures may render BDNF a more useful signal for 
communicating increases in neuronal activity. Finally, the source of BDNF in the two 
culture systems is different. In the case of visual cortical cultures, TTX inhibits neuronal 
activity by acting on the same cells in which scaling is measured (pyramidal neurons), 
whereas in the case of the NAc-PFC co-cultures, the TTX is acting on the excitatory PFC 
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neurons to reduce activity, whereas we are measuring scaling in the NAc MSN that are 
postsynaptic to these PFC neurons.
It remains unclear how elevation of BDNF levels for 24 h leads to scaling down of AMPAR 
levels. In parallel experiments, we showed that this BDNF treatment activates ERK but not 
AKT, mTOR or EF2; however, MEK1/2 inhibition did not prevent BDNF-induced 
decreases in AMPAR surface expression. Future studies should examine the possible role of 
BDNF signaling through PLCγ and whether BDNF regulates signaling molecules that have 
previously been implicated in bicuculline-induced scaling down of AMPAR transmission, 
such as Homer1a (Hu et al., 2010) and MeCP2 (Qiu et al., 2012; Zhong et al., 2012).
BDNF and cocaine-induced plasticity
BDNF has been shown to play an important role in animal models of cocaine addiction 
(McGinty et al., 2010; Pickens et al., 2011; Loweth et al., 2013) as has its downstream 
target, ERK (Lu et al., 2006; Girault et al., 2007; Whitfield et al., 2011). BDNF is highly 
expressed in many addiction-related brain regions (Meredith et al., 2002). Although BDNF 
mRNA is present in the NAc (e.g., Graham et al., 2007; Bahi et al., 2008), brain regions that 
project to the NAc, such as the PFC, provide a major source of BDNF through axonal 
transport (Altar et al., 1997). Many different types of cocaine exposure increase BDNF 
levels in the NAc (e.g., Grimm et al., 2003; Graham et al., 2007; Bahi et al., 2008), although 
the consequences for cocaine seeking are complex and depend on the regimen, the 
withdrawal time, and the subregion of NAc studied (Graham et al., 2007; 2009; Bahi et al., 
2008; Berglind et al., 2007, 2009; Whitfield et al., 2011; Li et al., 2013). In some cases, 
BDNF appears to modify addiction-related behaviors through its effects on glutamate 
transmission in the NAc (e.g., Berglind et al., 2009). However, even though both BDNF 
(above) and AMPARs (Wolf, 2010) are clearly important for addiction-related plasticity in 
the NAc, and prior studies in other cell types demonstrate that BDNF regulates AMPAR 
trafficking (Narisawa-Saito et al., 2002; Caldeira et al., 2007; Li & Keifer, 2008; 2009; 
Keifer & Zheng, 2010), it has been difficult to understand the relationship between cocaine’s 
effects on BDNF and AMPAR trafficking. By using PFC-NAc co-cultures to directly 
explore this relationship, we hope to define “rules” for BDNF-AMPAR relationships in NAc 
MSN that will help us interpret in vivo findings. For example, our 30 min results suggest 
that acute increases in BDNF levels may acutely increase AMPAR levels in NAc neurons. 
This could help explain a report that transient elevation of BDNF in the NAc shell after 
cocaine self-administration is important for promoting cocaine use and relapse in cocaine-
experienced animals (Graham et al., 2007), since elevation of NAc AMPAR levels is 
associated with increased motivation for cocaine (Wolf, 2010). Our 24 h results may be 
relevant to understanding consequences of the long-term elevation of BDNF observed in the 
NAc and other regions during withdrawal from extended access cocaine self-administration 
(Grimm et al., 2003). This type of cocaine exposure leads to a progressive intensification 
(“incubation”) of cocaine craving (Pickens et al., 2011) that ultimately depends upon 
increased CP-AMPAR levels in the NAc (Conrad et al., 2008). The finding that 24 h 
elevation of BDNF decreases AMPAR levels in cultured NAc neurons suggests that 
withdrawal-dependent in vivo increases in BDNF and CP-AMPAR levels are not causally 
related, a prediction that has recently received experimental support (Li et al., 2013).
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It is important to emphasize that there are many caveats associated with extrapolating from 
the present in vitro results to the role of BDNF in the intact NAc of cocaine-exposed 
rodents. A major limitation of our in vitro paradigm is that adding BDNF to the media 
obviously does not mimic physiological patterns of release. Indeed, acute and gradual 
increases in BDNF concentration elicit different effects on synaptic transmission (Ji et al., 
2010). There are also concerns about TrkB desensitization (Almeida et al., 2005). 
Furthermore, our co-culture model utilizes immature neurons and does not reproduce the full 
circuitry that regulates MSN activity. Despite these limitations, our results demonstrate that 
BDNF can regulate AMPAR trafficking in NAc MSN on different time-scales. This is 
relevant not only to addiction-related plasticity, but also to another pathological situation – 
social defeat and resultant social avoidance – that is mediated by a persistent elevation of 
BDNF signaling in the NAc (Berton et al., 2006; Krishnan et al., 2007).
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Surface expression and co-localization of GluA1 and GluA2 on NAc medium spiny neurons 
are robustly increased after acute BDNF treatment and decreased after long-term BDNF 
treatment of NAc/PFC co-cultures. (A) Representative images of GluA1, GluA2 and 
colocalized GluA1/A2 immunostaining on medium spiny neurons in NAc/PFC co-cultures. 
Co-cultures were treated with BDNF (25ng/mL) for 30 min or 24 h. Surface GluA1 (red) 
and GluA2 (green) were detected using live cell labeling. Scale bar, 2.5μm. (B-D) 
Quantification of the area of cell surface GluA1 (B), GluA2 (C), and GluA1/A2 co-
localization (D) (n = 18–26 cells/group). Results are shown as area of surface staining (mean 
+ SEM), normalized to the mean of the vehicle control group, which is indicated by the 
dashed line (control group: GluA1, 100 ± 14.67%; GluA2, 100 ± 10.23%; GluA1/A2, 100 ± 
18.12%). Data were analyzed using a one-way ANOVA on ranks followed by a Dunn’s test 
if group differences were found. *P < 0.05 vs. control.
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BS3 crosslinking followed by Western blotting reveals that acute BDNF treatment increases 
AMPAR surface expression in high-density NAc cultures. NAc cultures were treated with 
BDNF (25ng/mL) for 30 min or 24 h. Following BDNF treatment, surface proteins were 
crosslinked using BS3 and Western blotting was used to quantify surface (S) and 
intracellular (I) levels of AMPAR subunits. (A–B) Representative blots of GluA1 (left) and 
GluA2 (right) show the migration pattern for the AMPAR subunits. BS3 crosslinked surface 
proteins migrate at a higher molecular weight than the intracellular pool, which represents 
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unmodified receptors (~100kDa). (C-F) Effect of 30 min or 24 h incubation with BDNF on 
surface GluA1 (C), surface GluA2 (D), intracellular GluA1 (E), and intracellular GluA2 (F) 
(n = 4 wells/group). Error bars represent SEM. Data were analyzed using a one-way 
ANOVA followed by a Dunnett’s test if group differences were found. *P < 0.05 vs. 
control.
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Effect of BDNF treatment on phosphorylation of ERK1, ERK2, AKT, mTOR and eEF2 in 
high-density NAc cultures. These proteins were selected for analysis because they are 
downstream of BDNF-TrkB signaling. NAc cultures were stimulated with BDNF (25ng/mL) 
for 30 min or 24 h. Western blotting was used to determine the level of protein 
phosphorylation. The 30 min BDNF treatment increased phosphorylation of ERK1 (A), 
ERK2 (B), AKT (Ser 473) (C), and AKT (Thr 308) (D), but not mTOR (E), and eEF2 (F). 
The 24 h BDNF treatment only increased ERK1 and ERK2 phosphorylation. All data are 
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shown as phospho-protein normalized to the total level of target protein determined with a 
phosphorylation-independent antibody. Representative blots are shown below the graphs. 
Error bars represent SEM (n = 4 wells/group). Data were analyzed using a one-way 
ANOVA followed by a Dunnett’s test if group differences were found. *P < 0.05 vs. 
control.
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The increase in surface AMPAR levels induced by acute BDNF treatment of NAc/PFC co-
cultures requires MAPK activation but not the PI3 kinase pathway, whereas effects of long-
term BDNF are not altered by inhibitors of either pathway. Inhibition of the MAPK pathway 
with U0126 (U) prevented the increase in GluA1 and GluA2 surface expression and co-
localization observed after 30 min of BDNF (B) treatment, while inhibition of the PI3 kinase 
pathway with LY294002 (LY) had no effect (panels A-C). In contrast, the percent decrease 
in AMPAR subunit surface expression produced by 24 h of BDNF treatment did not differ 
between BDNF, U+BDNF or LY+BDNF groups (D-F). For these experiments, NAc/PFC 
co-cultures were treated with vehicle, BDNF (25ng/mL), U (10μM), LY (25μM), U+BDNF, 
or LY+BDNF for 30 min (A-C) or 24 h (D–F) (n = 17–25 cells/group). Surface GluA1 and 
GluA2 were measured using live cell staining. Results are presented as the area (mean + 
SEM) of surface GluA1 (A,D), GluA2 (B,E) or GluA1/A2 co-localization (C,F) for each 
time-point. Data were analyzed using a one-way ANOVA on ranks followed by a Dunn’s 
test. Analysis for 30 min experiment: *P < 0.05, B and LY+B groups vs. Control. Analysis 
for 24 h experiment: *P < 0.05, all BDNF groups (B, U+B, LY+B) vs. all non-BDNF 
exposed groups (Con, U, LY).
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BDNF mediates synaptic “scaling down” of AMPARs produced by a prolonged increase in 
excitatory transmission. Long-term treatment (24 h) of NAc/PFC co-cultures with the 
GABAA receptor bicuculline (BIC; 20 µM) produced a significant decrease in surface 
expression of GluA1 (A) and GluA2 (B) as well as GluA1/A2 co-localization (C). Co-
incubation with the membrane-impermeable extracellular scavenger of BDNF TrkB-Fc (T-
Fc, 0.5 µg/mL) prevented the decrease in GluA1 (A), GluA2 (B) and GluA1/A2 co-
localization (C) normally produced by BIC, while 24 h treatment with T-Fc alone produced 
trends towards increased AMPAR surface expression. Results are shown as area of surface 
staining (mean + SEM), normalized to the mean of the respective vehicle control group. 
Data were analyzed using a one-way ANOVA on ranks followed by a Dunn’s test if group 
differences were found. * P < 0.05 vs. control, # P < 0.05 vs. BIC.
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